Autopsy report · NCT04404569

Continued Treatment for Participants Enrolled in Studies of BXQ-350

“Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 3 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Bexion Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Neoplasms

Interventions

BXQ-350

Participants

5

Sites

3

Countries

United States

Trials that died the same way

• Long-Term Follow-Up Study of Patients Receiving ATL001
  “The long-term follow-up of patients is being migrated to the original (parent) study protocols (Trial ID: ATX-NS-001 / NCT: NCT04032847;Trial ID: ATX-ME-001 / NCT: NCT03997474). Consequently, the ATX-LTFU-001 study is being terminated by the Sponsor.” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.